EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis

Salvatore Petta iD, KyeongJin Kim iD, Giovanni Targher iD, Stefano Romeo, Silvia Sookoian iD, Ming-Hua Zheng iD, Alessio Aghemo iD, Luca Valenti iD

Liver International · 2025-11 · 45 (11)

DOI: 10.1111/liv.70407 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 27.10.2025. Verfasst von Salvatore Petta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology, PROMISE Department, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction‐associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of MASH and reduction in liver fibrosis. These benefits parallel weight loss and are accompanied by improved metabolic outcomes, including better glucose control and lipid profiles, as well as consistent benefits for cardiovascular and renal health. The treatment's safety profile is manageable, with gastrointestinal issues being the most frequent side effects, and no new safety concerns have been identified. Data on long‐term tolerability, treatment retention and clinical events are now awaited in people with MASH fibrosis. The evidence regarding semaglutide's ability to directly target the liver and improve liver damage in cirrhosis, and its impact on muscle mass in at‐risk populations, remains limited. Thus, in patients with advanced disease, it should be viewed primarily as a therapy that modifies metabolic disease. Practically, semaglutide is most suitable as a first‐line treatment to prevent liver complications for people with MASH and stage F2/F3 fibrosis with severe metabolic dysfunction, obesity, or type 2 diabetes who could benefit from both liver and cardiovascular‐renal improvements. Treatment should be tailoured to each individual, with ongoing monitoring of body weight, serum aminotransferase levels and direct measurement of liver fat and stiffness to guide therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesLiver CirrhosisFatty LiverNon-alcoholic Fatty Liver DiseaseHumansTreatment OutcomeLiverGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1MASHMASLDfibrosisincretin

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Section of Gastroenterology, PROMISE Department, University of Palermo, Palermo, Italy.
  • Department of Biomedical Sciences, College of Medicine, Incheon, Republic of Korea.
  • Program in Biomedical Science & Engineering, College of Medicine, Incheon, Republic of Korea.
  • Research Center for Controlling Intercellular Communication (RCIC), College of Medicine, Inha University, Incheon, Republic of Korea.
  • Department of Medicine, University of Verona, Verona, Italy.
  • Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.

ORCID-Profile: Salvatore Petta, KyeongJin Kim, Giovanni Targher, Silvia Sookoian, Ming-Hua Zheng, Alessio Aghemo, Luca Valenti

Zitieren

APA

Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S., Zheng, M. H., Aghemo, A., & Valenti, L. (2025). Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis. Liver International, 45(11). https://doi.org/10.1111/liv.70407

Vancouver

Petta S, Kim K, Targher G, Romeo S, Sookoian S, Zheng MH, et al. Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis. Liver International. 2025;45(11). doi:10.1111/liv.70407

BibTeX
@article{Petta2025,
  author = {Petta, Salvatore and Kim, KyeongJin and Targher, Giovanni and Romeo, Stefano and Sookoian, Silvia and Zheng, Ming-Hua and Aghemo, Alessio and Valenti, Luca},
  title = {Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {11},
  doi = {10.1111/liv.70407}
}
Kostenlos starten →